Scientific article

Chronic mTOR inhibition by rapamycin induces muscle insulin resistance despite weight loss in rats

Published inBritish journal of pharmacology, vol. 165, no. 7, p. 2325-2340
Publication date2012

mTOR inhibitors are currently used as immunosuppressants in transplanted patients and as promising anti-cancer agents. However, new-onset diabetes is a frequent complication occurring in patients treated with mTOR inhibitors such as rapamycin (Sirolimus). Here, we investigated the mechanisms associated with the diabetogenic effects of chronic Sirolimus administration in rats and in in vitro cell cultures.

  • Adipose Tissue/drug effects
  • Animals
  • Cells, Cultured
  • Diet, High-Fat/adverse effects
  • Fatty Liver/prevention & control
  • Glucose/metabolism
  • Glucose Clamp Technique
  • Glucose Intolerance/chemically induced
  • Glucose Transporter Type 4/metabolism
  • Immunosuppressive Agents/toxicity
  • Insulin/metabolism
  • Insulin Resistance
  • Male
  • Muscle Fibers, Skeletal/drug effects/metabolism
  • Muscle, Skeletal/drug effects/metabolism
  • Proto-Oncogene Proteins c-akt/metabolism
  • Rats
  • Rats, Wistar
  • Signal Transduction/drug effects
  • Sirolimus/toxicity
  • TOR Serine-Threonine Kinases/antagonists & inhibitors/metabolism
  • Weight Loss/drug effects
Citation (ISO format)
DEBLON, Nicolas et al. Chronic mTOR inhibition by rapamycin induces muscle insulin resistance despite weight loss in rats. In: British journal of pharmacology, 2012, vol. 165, n° 7, p. 2325–2340. doi: 10.1111/j.1476-5381.2011.01716.x
Main files (1)
Article (Published version)
ISSN of the journal0007-1188

Technical informations

Creation11/23/2012 4:39:00 PM
First validation11/23/2012 4:39:00 PM
Update time03/14/2023 7:54:30 PM
Status update03/14/2023 7:54:30 PM
Last indexation01/16/2024 12:48:56 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack